Drugs / Gadoteric Acid Meglumine Salt
Gadoteric Acid Meglumine Salt
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04776187 | Mar → Dec 2021 | nephrogenic systemic fibrosis | The Central Hospital of Lishui City | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gadoteric Acid Meglumine Salt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04776187 ↗ |
| Known as | Gadoteric Acid Meglumine Salt Injection | “Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid...” NCT04776187 ↗ |
| Known as | Jia Di Xian | “Generic name: Gadoteric Acid Meglumine Salt Injection; Commodity name: Jia Di Xian; Sample specifications: 15ml: 5.654g (a sterile solution containing 377mg/ml gadoteric acid...” NCT04776187 ↗ |
| Modality | Diagnostic / imaging agent | “gadolinium-based contrast agents” NCT04776187 ↗ |